The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...

UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened expression in the B cells of patients who have chronic lymphocytic leukemia (CLL).

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential ...

High incidence of new translocations in B-CLL detected by CD40L-enhanced cytogenetics (CEC): A new prognostic marker for infavorable survival outcome in patients with B-CLL No significant financial ...

Monoclonal B-cell lymphocytosis (MBL) is when you have a high number of identical B cells, under 5,000 per microliter, for at least 3 months. It usually causes no symptoms or need for active treatment ...

Ig V gene mutation status correlates well with clinical course and outcome regardless of surface membrane isotype expressed by B-CLL cells No significant financial relationships to disclose. This is ...

Monoclonal B-cell lymphocytosis (MBL) is a condition in which a person has an excessive amount of abnormal B cells, which are a type of white blood cell known as lymphocytes. The number of abnormal B ...

Nurix Therapeutics, Inc. has announced that data from its ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) will be presented at two major scientific conferences. The trial focuses on ...

This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and ...